CENTERVILLE, Mass.- UV Flu Technologies, Inc. (OTCBB: UVFT)(the "Company") is pleased to announce that Cardis Furniture (www.cardis.com) has chosen the Company's Viratech UV-400 as the air purifier to be combined with a premium Serta Mattress as the Ultimate Sleep System for promoting a sound sleep. Cardis was chosen as the first furniture chain in the country to launch this Serta sleep system, which is expected to be rolled out nationally over the next 12 months.
"We're thrilled to be associated with Cardis Furniture for the initial launch of the Serta Sleep System," said Jack Lennon, President of UV Flu Technologies. "Cardis is renown in the industry for their attention to customer service, and to issues that will promote a healthier environment for their customers, while they spend time indoors. Recent clinical studies have shown direct links between Indoor Air Pollution and sleep-related problems, as well as allergies, asthma, diabetes, and even stroke. Combining one of the best mattresses available, with a best-in-class Viratech Air Purifier, we believe will give customers the soundest sleep they have ever experienced."
"The combination of these two products we think will take the industry by storm," said Nick, Ron, and Pete Cardi, owners of Cardi's Furniture, in a joint statement. "Combining a specially made, Serta mattress, with one of the only residential FDA-cleared air purifiers, which kills airborne bacteria, odors, volatile organic compounds (VOC's), along with a host of other airborne contaminants, will keep our customers breathing better, sleeping sounder, and waking up happy and well-rested," echoed the brothers.
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.
In addition, the Company's RxAir subsidiary in Dallas, TX, makes one of the world's finest lines of hospital-grade HEPA filtration products. The RX-3000, the Company's main product, is currently in almost 450 hospitals internationally, is FDA-cleared as a Class II Medical Device, and has been shown to capture 99.99% of all airborne contaminants. The Company's product lines are in Hospitals, government buildings, casinos and restaurants around the world.
For more information, visit: www.uvflutech.com. Or www.rxair.com
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
SOURCE UV Flu Technologies, Inc.
Web Site: www.uvflutech.com